Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "Risk"

1413 News Found

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US
Drug Approval | March 07, 2025

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals


Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines
Drug Approval | March 04, 2025

Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines

The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations


Zydus Lifesciences to launch protection against new strain of influenza virus
News | February 27, 2025

Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives


India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


Indegene launches AI platform Cortex
Digitisation | February 25, 2025

Indegene launches AI platform Cortex

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain


5.1 lakh TB patients notified across India
Policy | February 23, 2025

5.1 lakh TB patients notified across India

Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities


Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg
Drug Approval | February 22, 2025

Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg

Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis


GSK's Nucala application for COPD accepted for review in China
Drug Approval | February 21, 2025

GSK's Nucala application for COPD accepted for review in China

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally